Literature DB >> 17877614

Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.

G Lescoat1, K Chantrel-Groussard, N Pasdeloup, H Nick, P Brissot, F Gaboriau.   

Abstract

OBJECTIVE: Iron loading has been observed to have a hyperproliferative effect on hepatocytes in vitro and on tumour cells in vivo; removal of this iron being required to induce antitumour activity.
MATERIAL AND METHODS: Antiproliferative effects of orally active tridentate iron chelator ICL670 (deferasirox) and bidentate iron chelator CP20 (deferiprone), mediated through the chelation of intracellular iron, were compared in rat hepatoma cell line FAO and human hepatoma cell line HUH7.
RESULTS: In FAO cell cultures, we have shown that ICL670 decreased cell viability and DNA replication and induced apoptosis more efficiently than an iron-binding equivalent concentration of CP20. Moreover, ICL670 decreased significantly the number of the cells in G(2)-M phase. In the HUH7 cell cultures, ICL670 and a four-time higher iron-binding equivalent concentration of CP20, decreased cell viability and DNA replication in the same range. CP20 increased the number of the cells in G(2)-M phase. However, ICL670 inhibited polyamine biosynthesis by decreasing ornithine decarboxylase mRNA level; in contrast, CP20 increased polyamine biosynthesis, particularly putrescine level, by stimulating spermidine-spermine N(1)-acetyl transferase activity that could activate the polyamine retro-conversion pathway. By mass spectrometry, we observed that ICL670 cellular uptake was six times higher than CP20.
CONCLUSIONS: These results suggest that ICL670 has a powerful antitumoural effect and blocks cell proliferation in neoplastic cells by a pathway different from that of CP20 and may constitute a potential adjuvant drug for anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17877614      PMCID: PMC6495977          DOI: 10.1111/j.1365-2184.2007.00468.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  32 in total

1.  The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.

Authors:  Karine Chantrel-Groussard; François Gaboriau; Nicole Pasdeloup; René Havouis; Hanspeter Nick; Jean-Louis Pierre; Pierre Brissot; Gérard Lescoat
Journal:  Eur J Pharmacol       Date:  2006-05-11       Impact factor: 4.432

2.  Effect of iron chelators on proliferation and iron uptake in hepatoma cells.

Authors:  A Kicic; A C Chua; E Baker
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

Review 3.  Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.

Authors:  John B Porter; Bernard A Davis
Journal:  Best Pract Res Clin Haematol       Date:  2002-06       Impact factor: 3.020

Review 4.  Oral iron chelators--development and application.

Authors:  Ding Y Liu; Zu D Liu; Robert C Hider
Journal:  Best Pract Res Clin Haematol       Date:  2002-06       Impact factor: 3.020

5.  Characterization of differentiated and dedifferentiated clones from a rat hepatoma.

Authors:  J Deschatrette; M C Weiss
Journal:  Biochimie       Date:  1974       Impact factor: 4.079

6.  Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines.

Authors:  N Rakba; P Loyer; D Gilot; J G Delcros; D Glaise; P Baret; J L Pierre; P Brissot; G Lescoat
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

7.  Effect of dietary iron deficiency or excess on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea.

Authors:  H J Thompson; K Kennedy; M Witt; J Juzefyk
Journal:  Carcinogenesis       Date:  1991-01       Impact factor: 4.944

8.  Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.

Authors:  François Gaboriau; Karine Chantrel-Groussard; Nafissa Rakba; Pascal Loyer; Nicole Pasdeloup; Robert C Hider; Pierre Brissot; Gérard Lescoat
Journal:  Biochem Pharmacol       Date:  2004-04-15       Impact factor: 5.858

9.  Low iron state is associated with reduced tumor promotion in a two-stage mouse skin carcinogenesis model.

Authors:  G Bhasin; H Kauser; M Athar
Journal:  Food Chem Toxicol       Date:  2002-08       Impact factor: 6.023

10.  Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines.

Authors:  Eiji Yasumoto; Kensuke Nakano; Tohru Nakayachi; Sufi Reza Md Morshed; Ken Hashimoto; Hirotaka Kikuchi; Hirofumi Nishikawa; Masami Kawase; Hiroshi Sakagami
Journal:  Anticancer Res       Date:  2004 Mar-Apr       Impact factor: 2.480

View more
  14 in total

1.  Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

Authors:  Yang-Sung Sohn; Anna-Maria Mitterstiller; William Breuer; Guenter Weiss; Z Ioav Cabantchik
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.

Authors:  Pascal Rouge; Alexandra Dassonville-Klimpt; Christine Cézard; Stéphanie Boudesocque; Roger Ourouda; Carole Amant; François Gaboriau; Isabelle Forfar; Jean Guillon; Emmanuel Guillon; Enguerran Vanquelef; Piotr Cieplak; François-Yves Dupradeau; Laurent Dupont; Pascal Sonnet
Journal:  Chempluschem       Date:  2012-11-01       Impact factor: 2.863

Review 3.  The role of iron in tumour cell proliferation.

Authors:  Juan Luis Steegmann-Olmedillas
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

4.  Hemochromatosis: a model of metal-related human toxicosis.

Authors:  Pierre Brissot; Thibault Cavey; Martine Ropert; François Gaboriau; Olivier Loréal
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-15       Impact factor: 4.223

5.  Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

Authors:  S J Ford; P Obeidy; D B Lovejoy; M Bedford; L Nichols; C Chadwick; O Tucker; G Y L Lui; D S Kalinowski; P J Jansson; T H Iqbal; D Alderson; D R Richardson; C Tselepis
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 6.  Targeting cancer by binding iron: Dissecting cellular signaling pathways.

Authors:  Goldie Y L Lui; Zaklina Kovacevic; Vera Richardson; Angelica M Merlot; Danuta S Kalinowski; Des R Richardson
Journal:  Oncotarget       Date:  2015-08-07

7.  Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.

Authors:  Issei Saeki; Naoki Yamamoto; Takahiro Yamasaki; Taro Takami; Masaki Maeda; Koichi Fujisawa; Takuya Iwamoto; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Koichi Uchida; Kenji Tani; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

8.  The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.

Authors:  Jehn-Chuan Lee; Kun-Chun Chiang; Tsui-Hsia Feng; Yu-Jen Chen; Sung-Ting Chuang; Ke-Hung Tsui; Li-Chuan Chung; Horng-Heng Juang
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

9.  Effects of oral iron chelator deferasirox on human malignant lymphoma cells.

Authors:  Jong Gwon Choi; Jung-Lim Kim; Joohee Park; Soonwook Lee; Seh Jong Park; Jun Suk Kim; Chul Won Choi
Journal:  Korean J Hematol       Date:  2012-09-25

10.  Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.

Authors:  Claire Legendre; Sylvie Avril; Catherine Guillet; Emmanuel Garcion
Journal:  BMC Cancer       Date:  2016-02-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.